我們報告一個罕見肝臟移植後再復發之肝癌個案：一名 69 歲原發肝癌男性因栓塞效果不 佳，在不符合米蘭規約（Milan criteria）條件下接受原位肝臟移植。移植後 16 個月之電腦斷層 影像顯示肝臟植體出現兩處復發病灶，病人因此接受經導管動脈化學栓塞及立體定位消融放射 治療之合併療法。病人對此治療方式耐受良好，在治療結束後追蹤的 28 個月中並無出現任何 急性或慢性之副作用。後續追蹤的影像檢查顯示治療部位完全緩解且無復發跡象。此個案報告 顯示，在肝臟移植後於肝植體復發之病人，併用經導管動脈化學栓塞及立體定位消融放射治 療，可能改善局部腫瘤控制及病人存活。

We describe a rare case of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT). A 69-year-old male underwent orthotopic LT for primary HCC outside of Milan criteria due to incomplete embolization. Sixteen months after LT, contrast-enhanced computed tomography (CT) showed two recurrent tumors in the liver graft. The patient underwent combined TACE and stereotactic ablative radiotherapy (SABR) to treat the recurrent lesions. Twenty-eight months after completion of combined treatment, the patient is doing well without experiencing any acute or chronic adverse effect. Surveillance images demonstrated complete regression and no evidence of recurrence. This case suggests that this dual-modality treatment in the post-transplant setting may help to improve local control and potentially survival in those recipients who develop recurrent HCC within the liver graft.